A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

Asthma Clinical Trial

— DOMINICA  

Official title:

Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05692180
• Other study ID #: D3250C00024
• Status: Recruiting
• Phase: Phase 3
• Start date: April 5, 2023
• Est. completion date: May 16, 2032

Study information

• Verified date: April 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.

Description:

A randomised, double-blind, parallel-group, placebo-controlled, time-to-first-asthma-exacerbation event study designed. There will be a screening period of 2 months to allow adequate time for the eligibility criteria to be evaluated. The screening period may be reduced to not lesser than 4 weeks from Visit 2a. Furthermore, the Screening Period may be extended up to 12 weeks (or longer, if deemed necessary by the investigator), to accommodate treatment. Visit 2 will be split into Part A (Visit 2a) and Part B (Visit 2b) to reassess eligibility prior to randomisation and first dose of study treatment administration. Patients will be randomised 1:1 to receive benralizumab or placebo. The treatment period will consist of 2 parts: double-blind (DB) treatment period and open-label extension (OLE) period. The initial placebo-controlled, DB treatment period will be of variable duration. The minimum duration of treatment in the DB treatment period for each patient will be 16 weeks. Patient will continue in the DB treatment period until the patient experiences an exacerbation or the required number of events have been observed in the study, whichever occurs sooner. All patients who experience an asthma exacerbation in the DB treatment period may enter the OLE period. The OLE period will be 48 weeks in the ≥ 12 to < 18-year-old age group and 2 years (104 weeks) in the ≥6 to < 12-year-old age group, where all patients will receive benralizumab. An end-of-the-treatment visit will occur 8 weeks after the last dose in the OLE.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: May 16, 2032
• Est. primary completion date: May 5, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• Capable of giving assent (signing the assent form) to participate in the study. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study specific procedures.
• Patient and the caregiver (where applicable) must be willing to and be able to answer questionnaires that are part of the study procedures.
• Male or female patients aged = 6 to < 18 years old.
• Patients with a diagnosis of eosinophilic asthma, defined by regional for at least 12 months prior to Visit 1.
• Patients with a diagnosis of severe asthma confirmed, evaluated, and managed by the clinical site for = 6 months prior to Visit 1.
• Patients with an exacerbation history of asthma exacerbations (defined as a requirement for systemic corticosteroids and/or hospitalization) within 12 months prior to Visit 1, OR,

1. 2 asthma exacerbations (defined as a requirement for systemic corticosteroids and/or hospitalization) per year within the 2 years prior to Visit 1 AND, one or

more of the following:

2. Currently on stable maintenance oral corticosteroids (OCS) used for at least 3 months prior to Visit 1, OR,

3. At least one of the 2 exacerbations that occurred in the year prior to Visit 1 resulted in hospitalisation.

• Patients on well-documented, stable treatment for asthma with high dose ICS and at least 1 additional controller medication, such as long-acting ß2 agonists (LABA), leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline, since at least 6 months prior to Visit 1.
• Eosinophilic airway inflammation that is related to asthma characterised as eosinophilic in nature as indicated by peripheral blood eosinophil count of = 300 cells/µL during screening OR a blood eosinophil count of 150 to 299 cells/µL and documentation of elevated eosinophils in bronchoalveolar lavage (BAL), sputum, or bronchial biopsy within the 2 years prior to Visit 1.
• = 70% compliance with maintenance asthma medication during the screening period based on the Paediatric Asthma Symptom - Observer reported (PASO) or Asthma Daily Diary.
• At least 70% daily PASO or Asthma Daily Diary completion during the entire screening period, with at least 50% PASO or Asthma Daily Diary completion in the 14-day period prior to randomisation.
• Pre-BD FEV1 = 95% PN or pre-BD FEV1/FVC ratio < 0.85 required. Patients with = 25 % increase in mean pre-BD FEV1 value during the screening period will be screen failed.
• ACQ-IA = 1.5 with no meaningful improvement (ACQ-IA change = -0.5) between screening and Visit 2a.
• Body weight = 15 kg.
• Females of childbearing potential (FOCBP) who are sexually active, as judged by the investigator, must commit to consistent and correct use of a highly effective and acceptable method of contraception

Exclusion Criteria:

• Clinically important pulmonary disease other than asthma or patients who have ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts
• Life-threatening asthma,
• Asthma exacerbation requiring use of systemic corticosteroids or increase in maintenance dose of OCS within 2 weeks prior to Visit 2a or acute upper/lower respiratory infection that requires antibiotics or antiviral medication within 2 weeks prior to the first dose of the IP (Visit 2b).
• Any disorder that is not stable in the opinion of the investigator and could affect the safety of the patient during the study, influence the findings of the studies or their interpretations or impede the patient's ability to complete the entire duration of the study.
• History of anaphylaxis to any biologic therapy.
• Current malignancy, or history of malignancy.
• A helminth parasitic infection
• Use of immunosuppressive medication
• Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
• Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to Visit 1
• Previously received benralizumab (MEDI-563).
• Participation in another interventional clinical study
• Patients with known hypersensitivity to benralizumab or any of the excipients of the product.
• Currently pregnant, breastfeeding, or lactating females.
• Previous randomisation in the present study.

Related Conditions & MeSH terms

• Asthma
• Pulmonary Eosinophilia

Intervention

Drug:
• Benralizumab
Benralizumab active solution will be administered SC to the patients.
• Placebo
Placebo solution will be administered SC to the patients.

Locations

Country	Name	City	State
Argentina	Research Site	Buenos Aires
Argentina	Research Site	Ciudad de Buenos Aire
Argentina	Research Site	Florencio Varela
Argentina	Research Site	Florida
Argentina	Research Site	Lobos
Argentina	Research Site	Mar del Plata
Argentina	Research Site	Mendoza
Argentina	Research Site	Mendoza
Argentina	Research Site	Rosario
Argentina	Research Site	Santa Fe
Canada	Research Site	Burlington	Ontario
Canada	Research Site	Edmonton	Alberta
Canada	Research Site	Hamilton	Ontario
Canada	Research Site	Montreal	Quebec
Canada	Research Site	Quebec
France	Research Site	Creteil
France	Research Site	Lyon
France	Research Site	Montpellier
France	Research Site	Nice cedex 1
France	Research Site	Paris
France	Research Site	Rouen Cedex
France	Research Site	Toulouse Cedex 9
Germany	Research Site	Essen
Germany	Research Site	Wesel
Italy	Research Site	Genova
Italy	Research Site	Milano
Italy	Research Site	Pavia
Italy	Research Site	Ponte San Pietro
Italy	Research Site	Roma
Italy	Research Site	Roma
Italy	Research Site	Verona
Korea, Republic of	Research Site	Cheongju-si
Korea, Republic of	Research Site	Jung-gu
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Poland	Research Site	Bialystok
Poland	Research Site	Krakow
Poland	Research Site	Lódz
Poland	Research Site	Rzeszów
Poland	Research Site	Skarzysko-Kamienna
Spain	Research Site	Badalona
Spain	Research Site	Barcelona
Spain	Research Site	Cartagena
Spain	Research Site	Esplugues de Llobregat
Spain	Research Site	Madrid
Spain	Research Site	Mérida
Spain	Research Site	Valencia
Taiwan	Research Site	Changhua
Taiwan	Research Site	Kaohsiung
Taiwan	Research Site	Taichung
Taiwan	Research Site	Taipei
Taiwan	Research Site	Taoyuan
United Kingdom	Research Site	Glasgow
United Kingdom	Research Site	Leicester
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Manchester
United States	Research Site	Brick	New Jersey
United States	Research Site	Bronx	New York
United States	Research Site	Charleston	South Carolina
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Cleveland	Ohio
United States	Research Site	Dallas	Texas
United States	Research Site	Kansas City	Missouri
United States	Research Site	Lafayette	Louisiana
United States	Research Site	Lincoln	Nebraska
United States	Research Site	Little Rock	Arkansas
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Mobile	Alabama
United States	Research Site	Montgomery	Alabama
United States	Research Site	Morgantown	West Virginia
United States	Research Site	New Orleans	Louisiana
United States	Research Site	Northfield	New Jersey
United States	Research Site	Ocala	Florida
United States	Research Site	Owensboro	Kentucky
United States	Research Site	San Antonio	Texas
United States	Research Site	Tucson	Arizona
United States	Research Site	Tyler	Texas
United States	Research Site	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Countries where clinical trial is conducted

United States,  Argentina,  Canada,  France,  Germany,  Italy,  Korea, Republic of,  Poland,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of patients with Adverse events (AEs) and Serious adverse events (SAEs)	The safety and tolerability of benralizumab will be evaluated.	From Screening period until EOT DB treatment period
Other	The AAER in the OLE period	The annualised rate of severe exacerbations in the OLE period will be assessed.	From Week 0 until the EOT OLE period
Primary	Time to first asthma exacerbation	The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.	From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period
Secondary	Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)	The effect of benralizumab on asthma control and symptoms will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period in Asthma symptom score	The effect of benralizumab on asthma control and symptoms will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period in rescue medication use	The effect of benralizumab on asthma control and symptoms will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period in night-time awakenings due to asthma	The effect of benralizumab on asthma control and symptoms will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period in peak expiratory flow (PEF)	The effect of benralizumab on asthma control and symptoms will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Serum benralizumab trough concentration	The pharmacokinetics of benralizumab will be characterised.	During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period
Secondary	Anti-benralizumab antibodies	The immunogenicity of benralizumab will be characterised.	During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period
Secondary	Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score	The effect of benralizumab on asthma health-related quality of life will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)	The effect of benralizumab on pulmonary function (FEV1) will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1	The effect of benralizumab on pulmonary function (FEV1) will be assessed.	From Baseline (Week 0) to EOT in DB treatment period
Secondary	The Annualised asthma exacerbation rate (AAER) in the DB treatment period	The asthma exacerbations reported during the DB treatment period of the study will be described.	From Screening until the EOT double blind treatment period